Table 3.
The incidence of symptoms indicating hepatic, renal and bladder toxicity in neuroblastoma patients with poor/intermediate and normal/rapid CYP2B6 metabolizer phenotypes.
| Poor/Intermediate CYP2B6 metabolizersa | Normal/Rapid CYP2B6 metabolizersa | P value | |
|---|---|---|---|
| Hepatotoxicity | |||
| ALT | 26.3% (5/19) | 60.0% (18/30) | 0.03 |
| GGT | 21.0% (4/19) | 40.0% (12/30) | 0.21 |
| Renal toxicity | |||
| Creatinine | 0.0% (0/19) | 6.6% (2/30) | 0.51 |
| Sodium | 5.2% (1/19) | 6.6% (2/30) | 1.00 |
| Potassium | 26.3% (5/19) | 26.6% (8/30) | 1.00 |
| Bloody urine | 0.0% (0/19) | 10% (3/30) | 0.27 |
Significant values are in bold.
aPatients’ CYP2B6 phenotypes were predicted on the basis of their CYP2B6 genotypes.